As directors push for technology transformation, a new survey reveals a striking confidence gap in risk oversight—especially ...

The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

23andMe’s bankruptcy judge approved a $16.5 million settlement with its cyber insurers that transfers remaining policy value for the benefit of data breach victims. Judge Brian C. Walsh of the US ...

[indiscernible] of Citi Global Healthcare Conference. My name is Geoff Meacham, I'm the senior biopharma analyst here. We're thrilled today to have Regeneron. And speaking on behalf of Regeneron, we ...

Canadians affected by a 23andMe data security breach two years ago have reached a proposed class-action settlement with the genetic testing company for approximately $4.49 million. Canada's privacy ...

Regeneron Pharmaceuticals is putting more money into gene editing, announcing Monday a partnership with Tessera Therapeutics to develop an experimental program for a rare liver and lung disease. At ...

When Carmen Thomas was growing up in Boston, her mom told her that her absent dad’s name was Joe Brown. So when she sent a saliva sample to 23andMe in her 20s and got a match with a Brown, she was ...

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...

FDA approved EYLEA HD for macular edema post-RVO with up to 8-week dosing after initial monthly doses. Phase 3 QUASAR trial showed non-inferior visual acuity gains with EYLEA HD compared to EYLEA.

After months of back-and-and forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...